|Title:||Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience||Authors:||Lin, Li-Ching
Wong, Natalie S.M.
Chua, Daniel T T
Lee, Sarah W M
|Keywords:||GIST; advanced; compassionate use; metastatic; ripretinib||Issue Date:||2022||Publisher:||FRONTIERS MEDIA SA||Journal Volume:||12||Source:||Frontiers in oncology||Abstract:||
Ripretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study. The INVICTUS study demonstrated significantly improved median progression-free survival (PFS) of 6.3 months and an overall survival (OS) insignificant benefit of ripretinib of 15.1 months as compared with placebo in 85 patients with advanced metastatic GIST. However, treatment outcome for the Chinese population, including in Taiwan and Hong Kong, was lacking.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.